MindWalk Holdings (HYFT) Stock Overview
Operates as a bio-native AI company. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
HYFT Community Fair Values
Create NarrativeSee what 23 others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
MindWalk Holdings Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.69 |
| 52 Week High | US$3.25 |
| 52 Week Low | US$0.27 |
| Beta | 0.70 |
| 1 Month Change | -18.36% |
| 3 Month Change | 29.01% |
| 1 Year Change | 170.40% |
| 3 Year Change | -64.16% |
| 5 Year Change | -83.39% |
| Change since IPO | -61.05% |
Recent News & Updates
Recent updates
Even With A 72% Surge, Cautious Investors Are Not Rewarding ImmunoPrecise Antibodies Ltd.'s (NASDAQ:IPA) Performance Completely
Jun 24
AI Driven Partnerships Will Open New Biotech Opportunities
Strategic partnerships and tech collaborations are anticipated to boost revenue streams, improve net margins, and enhance operational efficiency.ImmunoPrecise Antibodies Ltd.'s (NASDAQ:IPA) Shares Leap 28% Yet They're Still Not Telling The Full Story
May 04Will ImmunoPrecise Antibodies (NASDAQ:IPA) Spend Its Cash Wisely?
Apr 22Even With A 30% Surge, Cautious Investors Are Not Rewarding ImmunoPrecise Antibodies Ltd.'s (NASDAQ:IPA) Performance Completely
Jan 17ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Stock's 45% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Nov 24ImmunoPrecise Antibodies reports FQ1 results
Sep 14Shareholder Returns
| HYFT | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -6.1% | 13.9% | 1.6% |
| 1Y | 170.4% | -14.1% | 18.7% |
Return vs Industry: HYFT exceeded the US Life Sciences industry which returned -14.1% over the past year.
Return vs Market: HYFT exceeded the US Market which returned 18.7% over the past year.
Price Volatility
| HYFT volatility | |
|---|---|
| HYFT Average Weekly Movement | 25.3% |
| Life Sciences Industry Average Movement | 8.6% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.1% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: HYFT's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: HYFT's weekly volatility has increased from 19% to 25% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | 92 | Jennifer Bath | www.mindwalkai.com |
MindWalk Holdings Corp. operates as a bio-native AI company. It focuses on the integration of artificial intelligence, multi-omics data, and advanced laboratory research to accelerate the discovery and development of biologics. The company, through its LensAI platform and HYFT technology, it partners with pharmaceutical and biotechnology companies to drive de-risk drug development and unlock therapeutic possibilities.
MindWalk Holdings Corp. Fundamentals Summary
| HYFT fundamental statistics | |
|---|---|
| Market cap | US$81.70m |
| Earnings (TTM) | -US$21.59m |
| Revenue (TTM) | US$18.07m |
Is HYFT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HYFT income statement (TTM) | |
|---|---|
| Revenue | CA$25.21m |
| Cost of Revenue | CA$11.14m |
| Gross Profit | CA$14.07m |
| Other Expenses | CA$44.18m |
| Earnings | -CA$30.11m |
Last Reported Earnings
Jul 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.65 |
| Gross Margin | 55.80% |
| Net Profit Margin | -119.45% |
| Debt/Equity Ratio | 0% |
How did HYFT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/03 21:33 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/07/31 |
| Annual Earnings | 2025/04/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
MindWalk Holdings Corp. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robert Wasserman | Benchmark Company |
| Tania Armstrong-Whitworth | Cormark Securities Inc. |
| Swayampakula Ramakanth | H.C. Wainwright & Co. |